Source:http://linkedlifedata.com/resource/pubmed/id/16620971
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-12-12
|
pubmed:abstractText |
Therapeutic options for patients with relapse of MDS or high risk AML after allogeneic stem cell transplantation are limited. We here present the case of a 64-year-old female patient with MDS, who received peripheral blood stem cells from her HLA-identical brother after a non-myeloablative conditioning regimen. Two months after allogeneic transplantation she suffered from a relapse, now fulfilling WHO criteria for AML with a bone marrow blast count of 91%. We then decided to treat her with azacitidine, a DNA methyltransferase inhibitor with proven antileukemic activity. The patient achieved a complete haematological response after two cycles and full donor chimerism after a single dose of donor lymphocytes. We postulate that azacitidine acts through a direct reduction of malignant cells and may in addition augment the immunologic effects of donor lymphocyte infusions.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0145-2126
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
257-9
|
pubmed:meshHeading |
pubmed-meshheading:16620971-Acute Disease,
pubmed-meshheading:16620971-Antineoplastic Agents,
pubmed-meshheading:16620971-Azacitidine,
pubmed-meshheading:16620971-Female,
pubmed-meshheading:16620971-Follow-Up Studies,
pubmed-meshheading:16620971-Humans,
pubmed-meshheading:16620971-Leukemia, Myeloid,
pubmed-meshheading:16620971-Middle Aged,
pubmed-meshheading:16620971-Myelodysplastic Syndromes,
pubmed-meshheading:16620971-Recurrence,
pubmed-meshheading:16620971-Remission Induction,
pubmed-meshheading:16620971-Stem Cell Transplantation,
pubmed-meshheading:16620971-Transplantation, Homologous,
pubmed-meshheading:16620971-Transplantation Conditioning,
pubmed-meshheading:16620971-Treatment Outcome
|
pubmed:year |
2007
|
pubmed:articleTitle |
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
|
pubmed:affiliation |
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225 Düsseldorf, Germany. graef@med.uni-duesseldorf.de
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|